Triple-class refractory MM represents a particular challenge and is characterized by the progression during or shortly after treatment with the three main classes of anti-MM therapies: anti-CD38 monoclonal antibodies; (MoAbs), proteasome inhibitors; (PIs), and immunomodulators (IMiDs). Here, CD38 is linked to Miyoshi myopathy.